Final results revealed a significantly longer 3-year PFS (primary endpoint), but OS did not reach statistical significance since the EORTC 40983 trial was designed to detect an improvement in PFS but was not powered a priori to determine a difference in OS [ 7 ].
← all excerpts
Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial.
1
—
—